Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Medical News
  3. Practical Dermatology News

Football Star OBJ to Raise Awareness of Seborrheic Dermatitis With Arcutis

Odell Beckham
02/05/2025

NFL star Odell Beckham Jr. will help raise awareness of seborrheic dermatitis as part of a partnership with Arcutis Biotherapeutics, the company announced.

“Seb derm is such a common condition, but like me, many people may have a hard time trying to figure out what it is and what can be done about it,” Beckham said in a press release. “I want to inspire people not to be embarrassed or discouraged about their condition and instead be empowered to find a dermatologist and work together to find a treatment that works for them.”

Beckham said his seborrheic dermatitis started to bother him in his 20s, when he noticed white flaky skin throughout his beard and at his hairline, accompanied by a deep, burning itchy sensation that was extremely uncomfortable.

“After trying to figure out the cause for several years, I finally visited my dermatologist, who diagnosed me with seb derm and prescribed ZORYVE foam, which works really well for me,” he said. “Now I want to help others understand the condition, find a treatment option that works for them, and get a clear win for their skin.”

Seborrheic dermatitis affects approximately 10 million Americans. 

"Seborrheic dermatitis is a common condition that I see frequently in my practice, particularly among Black patients,” Karan Lal, DO, MS, FAAD, said in the release. “Seb derm is often misunderstood or misdiagnosed, and it can present differently in darker skin tones appearing more purple instead of red, so it is crucial to have a proper diagnosis. The key to managing seborrheic dermatitis effectively is finding the right treatment that works for each individual. ZORYVE is a unique treatment option because it is a steroid-free topical foam that can be used anywhere on the body, including the scalp, face and beard, to help clear skin and reduce itch.”

ZORYVE foam, 0.3%, from Arcutis, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. ZORYVE foam provides rapid disease clearance and significant reduction in itch, with nearly 80% of the 458 individuals using ZORYVE achieving clear or almost clear skin at Week 8 in two clinical trials, compared to 53% of the 225 individuals who used a vehicle (a foam not containing the active ingredient). In addition, 63% of the 206 individuals using ZORYVE had significant itch relief at Week 8, compared to 41% of the 98 people using a vehicle, in one of the clinical trials. ZORYVE is a once-daily steroid-free foam and was the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

Schedule13 Feb 2025